Medmain Inc. Established a Capital and Business Alliance with PSP and Raised 300 Million Yen to Accelerate the Promotion of Digital Pathology.
Medmain Inc., (CEO: Osamu Iizuka, Headquarters: Fukuoka-city, Fukuoka-prefecture, hereinafter “Medmain”), a provider of the digital pathology support solution “PidPort”, has established a capital and business alliance with PSP Corporation (CEO: Yoshihisa Yoda, Headquarters: Mitano-ku, Tokyo, hereinafter “PSP”), a medical image management system (PACS) provider.
We are pleased to announce that we have commenced a business partnership to promote digital pathology by raising 300 million yen through a third-party allotment of new shares with PSP as the underwriter.
■Overview of the Business Alliance
As a partner of healthcare professionals around the world, Medmain develops and provides PidPort, an AI-based cloud system that supports digital pathology, having a corporate mission as “to create a world where medical services can be accessed with technology anywhere, anytime.”
PSP also develops infrastructure platforms such as cloud storage infrastructure (NOBORI) and remote image diagnosis support infrastructure (ICHIGO) for medical institutions to provide services.
PSP and Medmain will collaborate by incorporating pathology diagnosis-related technologies (including AI development technologies) and systems developed and provided by Medmain into the infrastructure platform and services provided by PSP, as well as developing new systems such as pathology cloud PACS. PSP will also contribute to the further promotion of digital pathology by selling Medmain products to its customers.
■About PSP Corporation
PSP’s core business is the development and sales of medical image management systems (PACS). PSP has approximately 2,200 customers throughout Japan, and has a market share of over 22% in Japan in terms of the number of facilities in operation. In the future, PSP will not only expand its market share, but also promote more efficient system development by integrating and consolidating its products and services, and accelerate the development of new services such as AI-related business, medical information services for general users, and medical data utilization business.
■About Medmain Inc.
In the digital pathology field, Medmain develops and provides a digital pathology cloud system, “PidPort,” which enables remote diagnosis support, medical education, trainings and research meetings, and cloud research and development, in addition to services for digitalization of histopathological whole slide images. We also have succeeded in creating a proprietary technology that speeds up the development of pathology AI through transfer learning, and have accelerated the development speed. We have successfully developed 12 AI models for 7 organs so far.
■Company Profile
【Company Name】 Medmain Inc.
*Ministry of Economy, Trade and Industry J-START UP Selected Company https://www.j-startup.go.jp/en/startups/
【Date of Establishment】January 11, 2018
【Business Description】 Planning, Development, Operation and Sales of Medical Software and Cloud Services
【CEO】Osamu Iizuka
【Location】[Tokyo Office] 2-10-11 Minami-Aoyama 2F, Minato-ku, Tokyo / [Fukuoka Office] 2-4-5 Akasaka #104, Chuo-ku, Fukuoka City, Fukuoka Prefecture
【Related Websites】
【Corporate Website】 https://en.medmain.com/
【Product Website】 https://en.medmain.com/products
Cloud System with Digital Pathology AI “PidPort” https://pidport.medmain.com/en/
Digitalization Support Service for Histopathological Whole Slide Images https://imaging.medmain.com
【Contact Information】
Medmain Inc. PR Dept. pr-m@medmain.com
